07:00 , Oct 26, 2015 |  BC Week In Review  |  Clinical News

Aerius regulatory update

Merck submitted an NDA in Japan for desloratadine to treat allergic rhinitis, hives and itching resulting from skin diseases. Merck markets the histamine H1 receptor (HRH1) antagonist as Clarinex in the U.S. and as Aerius...
08:00 , Jan 12, 2015 |  BC Week In Review  |  Company News

Merck, Kyorin deal

Merck’s MSD K.K. subsidiary granted Kyorin co-marketing and co-promotion rights in Japan to desloratadine. The second-generation histamine H1 receptor antagonist is in Phase III testing to treat allergic rhinitis. MSD will receive an upfront payment...
08:00 , Jan 7, 2010 |  BC Innovations  |  Targets & Mechanisms

HCV cache: the list

Researchers at The Scripps Research Institute have used a cell-based model of HCV infection to identify compounds on the market or in development for other indications that could be repurposed to treat HCV. 1 But...
07:00 , Mar 23, 2009 |  BC Week In Review  |  Company News

Schering-Plough inflammation news

Schering-Plough will pay $165 million under a preliminary settlement with shareholders in a class action suit filed in the U.S. District Court for the District of New Jersey in 2001 regarding a delay in approval...
08:00 , Feb 25, 2008 |  BC Week In Review  |  Clinical News

Aerius regulatory update

EMEA's CHMP issued a positive opinion to extend the label for desloratidine to include treatment of all types of urticaria. Schering-Plough markets the histamine H1 receptor antagonist already as Aerius, Azomyr and Neoclarityn in the...
07:00 , May 28, 2007 |  BC Week In Review  |  Clinical News

Aerinaze desloratadine/pseudoephedrine regulatory update

CHMP issued a positive opinion for the approval of Aerinaze, a combination of 2.5 mg desloratadine and 120 mg pseudoephedrine to treat seasonal allergic rhinitis accompanied by nasal congestion. Schering-Plough Corp. (SGP), Kenilworth, N.J.  ...
07:00 , May 7, 2007 |  BC Week In Review  |  Clinical News

Clarinex desloratadine regulatory update

The EC approved an MAA for 2.5 and 5 mg Aerius orally disintegrating tablets to treat allergic rhinitis and chronic idiopathic urticaria (CIU) in patients 6 years and older, and 0.5 mg/ml Aerius oral solution...
08:00 , Dec 4, 2006 |  BC Week In Review  |  Clinical News

Clarinex desloratadine: Post-marketing study data

Data from a study conducted by the Drug Safety Research Unit (DSRU) examining the records of >24,000 allergic rhinitis patients without asthma showed that the incidence of drowsiness and sedation alone or in combination with...
07:00 , Sep 11, 2006 |  BC Week In Review  |  Clinical News

Clarinex desloratadine update

SGP began 2 international ACCEPT trials in about 1,300 patients. The trial will evaluate efficacy, impact on quality of life, productivity and pharmacoeconomics of Aerius in patients with persistent or intermittent allergic rhinitis. Schering-Plough Corp....
08:00 , Feb 6, 2006 |  BC Week In Review  |  Clinical News

Clarinex-D 12 Hour regulatory update

FDA approved an NDA for Clarinex-D 12 hour extended-release tablets to treat nasal and non-nasal symptoms of seasonal allergic rhinitis, including nasal congestion, in patients ages 12 and older. The twice-daily combination of 2.5 mg...